BioCentury
ARTICLE | Product Development

Nkarta looks to reduce manufacturing costs with new cell therapy plant

The facility will be capable of manufacturing NK cell therapies for $2,000 per dose

July 14, 2021 4:56 PM UTC

Nkarta announced Wednesday plans to build an integrated hub comprising manufacturing and R&D facilities and company headquarters in South San Francisco.

Building a proprietary manufacturing capacity, and co-locating it with R&D, is critical to ensuring quality, reducing costs and enabling rapid iteration of manufacturing technologies, Paul Hastings, president and CEO of Nkarta Inc. (NASDAQ:NKTX), told BioCentury. ...

BCIQ Company Profiles

Nkarta Inc.